Simmons Holly C, Finney Joel, Kotaki Ryutaro, Adachi Yu, Moseman Annie Park, Watanabe Akiko, Song Shengli, Robinson-McCarthy Lindsey R, Le Sage Valerie, Kuraoka Masayuki, Moseman E Ashley, Kelsoe Garnett, Takahashi Yoshimasa, McCarthy Kevin R
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
mBio. 2025 Jun 11;16(6):e0089225. doi: 10.1128/mbio.00892-25. Epub 2025 May 20.
Influenza infection and vaccination impart strain-specific immunity that protects against neither seasonal antigenic variants nor the next pandemic. However, antibodies directed to conserved sites can confer broad protection. Here, we identify and characterize a class of human antibodies that engage a previously undescribed, conserved epitope on the influenza hemagglutinin (HA) protein. Prototype antibody S8V1-157 binds at the normally occluded interface between the HA head and stem. Antibodies to this HA head-stem interface epitope are non-neutralizing but protect against lethal influenza infection in mice. These antibodies bind to most influenza A subtypes and seasonal human variants, and are present at low frequencies in the memory B cell populations of multiple human donors. Vaccines designed to elicit these antibodies might contribute to "universal" influenza immunity.
Antibodies to the influenza virus hemagglutinin (HA) protein confer the strongest protection against infection. Human antibodies elicited by infection and/or vaccination fail to protect against antigenically novel animal, pandemic, or human seasonal viruses. Improved vaccines are needed. We identify a novel class of antibodies that bind most divergent HA subtypes and all seasonal human HA antigenic variants tested. These antibodies confer protection from lethal influenza challenge in animal models. The corresponding epitope on the HA head is occluded by its interaction with the stem and is inaccessible in the well-resolved prefusion state. The immunogenicity of this head-stem interface indicates that poorly understood conformations of HA presenting widely conserved surfaces are explored in biochemical, cell-based, and assays. Head-stem interface antibodies warrant further investigation as an avenue to improve influenza vaccines and therapeutics.
流感感染和疫苗接种会产生毒株特异性免疫,这种免疫既不能抵御季节性抗原变异体,也无法预防下一次大流行。然而,针对保守位点的抗体可提供广泛保护。在此,我们鉴定并表征了一类人类抗体,这类抗体与流感血凝素(HA)蛋白上一个此前未被描述的保守表位结合。原型抗体S8V1 - 157在HA头部和茎部之间通常被遮蔽的界面处结合。针对该HA头部 - 茎部界面表位的抗体不具有中和作用,但能保护小鼠免受致死性流感感染。这些抗体可与大多数甲型流感亚型和季节性人类变异体结合,并且在多个人类供体的记忆B细胞群体中以低频率存在。设计用于引发这些抗体的疫苗可能有助于实现“通用”流感免疫。
针对流感病毒血凝素(HA)蛋白的抗体对感染具有最强的保护作用。由感染和/或疫苗接种引发的人类抗体无法抵御抗原性新颖的动物、大流行或人类季节性病毒。因此需要改进疫苗。我们鉴定出一类新型抗体,它们能与大多数差异较大的HA亚型以及所有测试的人类季节性HA抗原变异体结合。这些抗体在动物模型中可保护机体免受致死性流感攻击。HA头部上的相应表位通过与茎部的相互作用而被遮蔽,在解析良好的预融合状态下无法接近。这种头部 - 茎部界面的免疫原性表明,在生化、基于细胞的以及相关试验中,人们对呈现广泛保守表面的HA的构象了解甚少。头部 - 茎部界面抗体作为改进流感疫苗和治疗方法的途径值得进一步研究。